Categorynews

Vertex Appoints Charles Wagner as Chief Financial Officer

April 2, 2019 Off By BusinessWire

BOSTON–(BUSINESS WIRE)–Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the
appointment of Charles (Charlie) Wagner as Executive Vice President and
Chief Financial Officer (CFO), effective April 10, 2019. Mr. Wagner will
report directly to Vertex Chairman, President and Chief Executive
Officer Jeffrey Leiden, M.D., Ph.D., and oversee the finance, internal
audit, investor relations, and global security and facilities functions.
Mr. Wagner joins Vertex with deep corporate finance and health care
experience, including more than a decade in public and private company
CFO roles.

“Charlie is a proven finance leader with extensive experience working in
a public company setting, and he will be a tremendous asset to Vertex
and our strong team,” said Dr. Leiden. “As we continue to build Vertex
for the future, Charlie’s strategic mindset, operational expertise, and
broad leadership experience will prove invaluable. I’d like to thank our
interim CFO, Paul Silva, for his contributions and leadership. Paul will
continue in his role as Corporate Controller upon Charlie’s arrival.”

Mr. Wagner joins Vertex from Ortho Clinical Diagnostics, Inc. – a
Carlyle Group portfolio company, where he served as CFO and EVP,
Finance. In this role, he had leadership responsibilities for all
aspects of finance, accounting, tax, treasury, global information
systems, lender relations, and acquisitions and divestitures, as well as
shared responsibility for several enterprise-wide projects. Prior to
this, Mr. Wagner served as CFO for publicly- traded Bruker Corporation,
Progress Software Corporation and Millipore Corporation. In addition to
his corporate finance roles, Mr. Wagner served as an advisor at Bain &
Company and Coopers & Lybrand. He received his BS in accounting from
Boston College and his MBA from Harvard Business School.

“I am excited to be joining Vertex at such a dynamic time as the company
continues to deliver more transformational medicines for cystic fibrosis
patients and accelerates its pipeline of innovative and novel
life-changing treatments for patients with other serious diseases,” said
Mr. Wagner. “I look forward to working with Vertex’s senior leadership
team and employees to help the company continue to drive value through
its remarkable innovation.”

About Vertex

Vertex is a global biotechnology company that invests in scientific
innovation to create transformative medicines for people with serious
and life-threatening diseases. In addition to clinical development
programs in CF, Vertex has more than a dozen ongoing research programs
focused on the underlying mechanisms of other serious diseases.

Founded in 1989 in Cambridge, Mass., Vertex’s headquarters is now
located in Boston’s Innovation District. Today, the company has research
and development sites and commercial offices in the United States,
Europe, Canada, Australia and Latin America. Vertex is consistently
recognized as one of the industry’s top places to work, including being
named to Science magazine’s Top Employers in the life sciences ranking
for nine years in a row.

For additional information and the latest updates from the company,
please visit www.vrtx.com.

Special Note Regarding Forward-looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, including, without
limitation, the statements in the second and fourth paragraphs of this
press release. While Vertex believes the forward-looking statements
contained in this press release are accurate, there are a number of
factors that could cause actual events or results to differ materially
from those indicated by such forward-looking statements. Those risks and
uncertainties include, among other things, risks listed under Risk
Factors in Vertex’s annual report and quarterly reports filed with the
Securities and Exchange Commission. Vertex disclaims any obligation to
update the information contained in this press release as new
information becomes available.

(VRTX-GEN)